Published 2022
| Version v1
Publication
Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy
- Creators
- Lambertini, Matteo
- Fielding, Shona
- Loibl, Sibylle
- Janni, Wolfgang
- Clark, Emma
- Franzoi, Maria Alice
- Fumagalli, Debora
- Caballero, Carmela
- Arecco, Luca
- Salomoni, Sharon
- Ponde, Noam F
- Poggio, Francesca
- Kim, Hee Jeong
- Villarreal-Garza, Cynthia
- Pagani, Olivia
- Paluch-Shimon, Shani
- Ballestrero, Alberto
- Del Mastro, Lucia
- Piccart, Martine
- Bines, Jose
- Partridge, Ann H
- de Azambuja, Evandro
- Others:
- Lambertini, Matteo
- Fielding, Shona
- Loibl, Sibylle
- Janni, Wolfgang
- Clark, Emma
- Franzoi, Maria Alice
- Fumagalli, Debora
- Caballero, Carmela
- Arecco, Luca
- Salomoni, Sharon
- Ponde, Noam F
- Poggio, Francesca
- Kim, Hee Jeong
- Villarreal-Garza, Cynthia
- Pagani, Olivia
- Paluch-Shimon, Shani
- Ballestrero, Alberto
- Del Mastro, Lucia
- Piccart, Martine
- Bines, Jose
- Partridge, Ann H
- de Azambuja, Evandro
Description
Young age at breast cancer (BC) diagnosis has historically been a rationale for overtreatment. Limited data with short follow-up exist on the prognostic value of age at diagnosis in HER2-positive BC and the benefit of anti-HER2 therapy in young patients.
Additional details
- URL
- https://hdl.handle.net/11567/1100552
- URN
- urn:oai:iris.unige.it:11567/1100552
- Origin repository
- UNIGE